Exhibit 107

Calculation of Filing Fee Tables

S-1

(Form Type)

CURATIVE BIOTECHNOLOGY INC.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

	Security Type	Security Class Title	Fee Calculation or Carry Forward Rule	Amount Registered		Proposed Maximum Offering Price Per Share		Maximum Aggregate Offering Price (1)(2)(3)		Fee Rate		Amount of Registration Fee		Carry Forward Form Type		Carry Forward File Number		Carry Forward Initial Effective Date		Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward
	Newly Registered Securities
Fees to be Paid	Equity	Common Stock, $0.001 par value per share			1,750,000	$	4.00	$	7,000,000	$	0.00014760	$	1,033.20		S-1		333-268194			$	2,587.87
Fees to be Paid	Equity	Representative’s Warrants	457(g)
Fees to be Paid	Equity	Common Stock issuable upon exercise of Representative’s Warrants (4)	457(g)		87,500	$	5.00	$	437,500	$	0.00014760	$	64.575
Fees to be Paid	Equity	Selling Stockholders Warrants	457(g)
Fees to be Paid	Equity	Common Stock issuable upon exercise of Selling Stockholders Warrants (5)	457(g)		90,476	$	0.04	$	3,619.04	$	0.00014760	$	0.53
Fees to be Paid	Equity	Pre-Existing Selling Stockholders Warrants	457(g)
Fees to be Paid	Equity	Common Stock issuable upon exercise of Pre-Existing Selling Stockholders Warrants (5)	457(c)		86,301	$	0.04	$	3,452.04	$	0.00014760	$	0.50
Fees to be Paid	Equity	Common Stock Issuable Upon Conversion of Series B Preferred Stock by Selling Stockholders (6)	457(c)		333,333	$	4.00	$	1,333,332	$	0.00014760	$	196.80
Fees Previously Paid	—	—	—		—		—		—		—
	Carry Forward Securities
Carry Forward Securities	—	—	—		—		—		—		—		—		—		—		—		—
Total Offering Amounts								$	8,777,903.08			$	1,295.61
Total Fees Previously Paid												$	2,587.87
Total Fee Offset												$	1,292.26
Net Fee Due												$	0

(1)	Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the “Securities Act”).
(2)	Pursuant to Rule 416(a) under the Securities Act of 1933, this registration statement shall also cover an indeterminate number of shares that may be issued and resold resulting from stock splits, stock dividends or similar transactions.
(3)	Includes Common Stock to cover the exercise of the over-allotment option granted to the underwriter.
(4)	Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act. The warrants, or the Representative’s Warrants, are exercisable at a per share exercise price equal to 125% of the public offering price. As estimated solely for the purpose of recalculating the registration fee pursuant to Rule 457(g) under the Securities Act, the proposed maximum aggregate offering price of the shares of common stock issuable upon exercise of the Representative’s Warrants is equal to 125% of $350,000 (which is equal to 5% of $7,000,000).
(5)	Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) under the Securities Act. In accordance with Rule 457(c) under the Securities Act, the aggregate offering price for the shares of common stock issuable upon exercise of the Selling Stockholders warrants to be sold by the Selling Stockholders is calculated based on the $10.76 average of the high and low prices reported on the OTC Pink Sheets for May 3, 2024, on an assumed post reverse stock split basis.
(6)	In accordance with Rule 457(g) under the Securities Act, the aggregate offering price for the shares of common stock underlying the shares of Series B Preferred Stock to be sold by the Selling Stockholders is calculated based on an assumed conversion price of $3.00.